Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 43Unknown 10Terminated 7Active not recruiting 5Recruiting 3Withdrawn 2Suspended 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 40Breast Neoplasms 38Prostatic Neoplasms 24Colorectal Neoplasms 23Uterine Cervical Neoplasms 16Carcinoma, Non-Small-Cell Lung 13Anxiety Disorders 13Stomach Neoplasms 9Lymphoma, Follicular 9Leukemia, Myeloid, Acute 9Carcinoma, Hepatocellular 9Brain Neoplasms 9Lung Neoplasms 8Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Esophageal Neoplasms 7Sarcoma 6Ovarian Neoplasms 6Esophageal Squamous Cell Carcinoma 6Depression 6Colonic Neoplasms 6Uterine Cervical Dysplasia 5Small Cell Lung Carcinoma 5Pain 5Glioma 5Epilepsy 5Dementia 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × Neurotoxicity Syndromes × Clear all
NCT06950190 2025-08-12

(ECCPC)

Ellis Medicine

Phase 3 Enrolling by invitation
100 enrolled

Chemotherapy-Related Cognitive Impairment, Neurotoxicity Syndromes, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡